Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.56 |
| ▸ | GAA | P10253 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | PARP1 | P09874 | 4/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21359608 | 1.00 | ALDH1A1 (0.56) | ALDH1A1KDM4EMAPTGAAKMT2A | |
| SCHEMBL3322085 | 0.93 | ALDH1A1 (0.50) | ALDH1A1KDM4EMAPTGAAKMT2A | |
| SCHEMBL15835183 | 0.81 | ALDH1A1 (0.51) | ALDH1A1KDM4EMAPTGAAKMT2A | |
| SCHEMBL3457347 | 0.81 | ALDH1A1 (0.51) | ALDH1A1KDM4EMAPTGAAKMT2A | |
| SCHEMBL7968278 | 0.73 | ALDH1A1 (1.00) | ALDH1A1KDM4EMAPTGAAKMT2A | |
| SCHEMBL7981536 | 0.73 | ALDH1A1 (1.00) | ALDH1A1KDM4EMAPTGAAKMT2A | |
| SCHEMBL10502579 | 0.73 | ALDH1A1 (1.00) | ALDH1A1KDM4EMAPTGAAKMT2A | |
| SCHEMBL12228286 | 0.72 | ALDH1A1 (0.44) | ALDH1A1KDM4EMAPTGAAKMT2A | |
| Cyclo(Prolylglycyl) SCHEMBL3016264 | 0.72 | ALDH1A1 (0.48) | ALDH1A1KDM4EMAPTGAAKMT2A | |
| SCHEMBL21736594 | 0.72 | ALDH1A1 (0.48) | ALDH1A1KDM4EMAPTGAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1042315-B1 | CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE CO CHEM PHARM FAB (DE) | 2004-04-14 | — | — | EP | claimed |
| US-5338859-A | Reacting a hydantoin with a calcium base; crystallization; precipitation; separation | HOECHST CELANESE CORPORATION (US) | 1994-08-16 | — | — | US | claimed |
| US-4436910-A | SAPONIFICATION | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1984-03-13 | — | — | US | claimed |
| CN-118344315-A | Preparation and application of trifluoro thioether (sulfoxide) aromatic amine derivative | 顺毅股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-10722514-B2 | Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof | RAPT THERAPEUTICS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20190142834-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2019-05-16 | — | — | US | disclosed |
| US-8729096-B2 | Imidazolidine-2,4-dione derivatives as N-formyl peptide receptor 2 modulators | ALLERGAN, INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8680103-B2 | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-03-25 | — | — | US | disclosed |
| US-20130217720-A1 | IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS N-FORMYL PEPTIDE RECEPTOR 2 MODULATORS | ALLERGAN, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| EP-2228065-B1 | Heterocyclo inhibitors of potassium channel function | BRISTOL MYERS SQUIBB CO (US) | 2012-12-26 | — | — | EP | disclosed |
| US-20120302750-A1 | PROCESS FOR PREPARING 2-AMINOTHIAZOLE-5-AROMATIC CARBOXAMIDES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-11-29 | — | — | US | disclosed |
| EP-0191814-A1 | PROTEIN ABSORPTION ENHANCING AGENTS. | SURVIVAL TECHNOLOGY (US) | 1986-08-27 | — | — | EP | disclosed |
| EP-0191056-A1 | t-PA COMPOSITION AND METHOD OF GETTING INTO BLOOD STREAM | SURVIVAL TECHNOLOGY, INC. (US) | 1986-08-20 | — | — | EP | disclosed |
| WO-1986001104-A1 | t-PA COMPOSITION AND METHOD OF GETTING INTO BLOOD STREAM | SURVIVAL TECHNOLOGY, INC. (US) | 1986-02-27 | — | — | WO | disclosed |
| WO-1986001109-A1 | PROTEIN ABSORPTION ENHANCING AGENTS | SURVIVAL TECHNOLOGY, INC. (US) | 1986-02-27 | — | — | WO | disclosed |
| WO-1986001110-A1 | ABSORPTION ENHANCING AGENTS | SURVIVAL TECHNOLOGY, INC. (US) | 1986-02-27 | — | — | WO | disclosed |
| US-4436910-A | SAPONIFICATION | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1984-03-13 | — | — | US | disclosed |
| US-4012259-A | DICARBONYL METHYLENE GROUP ON A 2,5-DIOXO-1-IMIDAZOLIDINE IS A YELLOW COUPLER | FUJI PHOTO FILM CO., LTD. (JA) | 1977-03-15 | — | — | US | disclosed |
| US-3948933-A | CNS DEPRESSANTS, TRANQUILIZERS, ANXIOLYTIC | GRUPPO LEPETIT S.P.A. (IT) | 1976-04-06 | — | — | US | disclosed |
| US-3948933-A | CNS DEPRESSANTS, TRANQUILIZERS, ANXIOLYTIC | GRUPPO LEPETIT S.P.A. (IT) | 1976-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302750-A1 | PROCESS FOR PREPARING 2-AMINOTHIAZOLE-5-AROMATIC CARBOXAMIDES AS KINASE INHIBITORS | MAP3K5, MAP3K2, MAP3K20 | ALDH1A1 2694/4885KDM4E 562/4885MAPT 754/4885 |
| US-20190142834-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | USP7, SENP7, USP8 | ALDH1A1 3068/4885KDM4E 1989/4885MAPT 2789/4885 |
| US-10722514-B2 | Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof | USP7, SENP7, USP8 | ALDH1A1 3068/4885KDM4E 1989/4885MAPT 2789/4885 |
| US-20130217720-A1 | IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS N-FORMYL PEPTIDE RECEPTOR 2 MODULATORS | FPR2, FPR1, FPR3 | ALDH1A1 4657/4885KDM4E 4612/4885MAPT 4759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.